Medical Microbiology and Immunology

, Volume 193, Issue 4, pp 173–180

Miltefosine (Impavido): the first oral treatment against leishmaniasis

  • H. Sindermann
  • S. L. Croft
  • K. R. Engel
  • W. Bommer
  • H. J. Eibl
  • C. Unger
  • J. Engel
Original Investigation

DOI: 10.1007/s00430-003-0201-2

Cite this article as:
Sindermann, H., Croft, S.L., Engel, K.R. et al. Med Microbiol Immunol (2004) 193: 173. doi:10.1007/s00430-003-0201-2

Abstract

Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy.

Keywords

Visceral leishmaniasis Miltefosine Oral activity Antimonial resistance 

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • H. Sindermann
    • 1
  • S. L. Croft
    • 2
  • K. R. Engel
    • 3
  • W. Bommer
    • 3
  • H. J. Eibl
    • 4
  • C. Unger
    • 5
  • J. Engel
    • 1
  1. 1.Zentaris AGFrankfurt am MainGermany
  2. 2.London School of Hygiene and Tropical MedicineLondonUK
  3. 3.Georg-August-University of GöttingenInstitute of HygieneGöttingenGermany
  4. 4.Max-Planck-Institut für Biophysikalische ChemieGöttingenGermany
  5. 5.Klinik für TumorbiologieFreiburgGermany

Personalised recommendations